GLP-1 MEDICATIONS AND SLEEP APNEA: THE FIRST DRUG APPROVED FOR OSA

A Historic First: A Drug Approved for Sleep Apnea

For decades, the only real treatment options for obstructive sleep apnea (OSA) were CPAP machines, dental devices, or surgery. In late 2024, that changed when tirzepatide became the first medication ever granted FDA approval specifically for treating OSA in adults with obesity — a landmark moment in sleep medicine.

This matters disproportionately for men. Men are 2–3 times more likely than women to develop obstructive sleep apnea, and the condition is strongly linked to obesity, cardiovascular disease, low testosterone, and erectile dysfunction — a cascade of health problems that feed into each other.

What the SURMOUNT-OSA Trials Showed

The FDA approval was based on the SURMOUNT-OSA clinical trials, which tested tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity. The results were striking.

Participants taking tirzepatide experienced a reduction of approximately 20–24 events per hour in their apnea-hypopnea index (AHI) compared to placebo. To put that in perspective, an AHI of 15–30 is considered moderate sleep apnea, and 30+ is severe. Many participants dropped below the threshold for clinical diagnosis entirely.

Between 43% and 51.5% of participants met the criteria for disease resolution — meaning their sleep apnea was effectively eliminated, not just managed. This is something CPAP can achieve mechanically each night, but tirzepatide appeared to address the underlying cause: excess weight compressing the airway.

Beyond the AHI numbers, participants reported significant improvements in daytime sleepiness, sleep quality, and overall functioning — the subjective quality-of-life improvements that matter most day to day.

Why This Matters Specifically for Men

Sleep apnea isn’t just about snoring. In men, untreated OSA creates a destructive feedback loop:

• Testosterone suppression: Fragmented sleep disrupts the pulsatile release of testosterone, which peaks during deep sleep. Men with untreated OSA have significantly lower testosterone levels.
• Cardiovascular strain: Repeated oxygen desaturation events stress the heart. The SELECT trial showed semaglutide reduced major cardiovascular events by 20% — and resolving sleep apnea adds to that cardiovascular protection.
• Weight gain cycle: Poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), making weight loss harder. It also increases cortisol, which promotes visceral fat storage.
• Erectile dysfunction: OSA is independently associated with ED, likely through both vascular and hormonal pathways.

By addressing the root cause (excess weight) rather than just the symptom (airway obstruction), GLP-1 medications can potentially break this entire cycle simultaneously.

Semaglutide vs. Tirzepatide for Sleep Apnea

While tirzepatide received the specific FDA indication for OSA, semaglutide also shows benefits for sleep-disordered breathing through weight loss. The difference is that tirzepatide’s dual GLP-1/GIP mechanism tends to produce greater weight loss (up to 22.5% in the SURMOUNT trials vs. about 15% for semaglutide in STEP trials), which translates to more significant airway improvement.

If you’ve been diagnosed with moderate-to-severe OSA and have a BMI over 30, tirzepatide may be the stronger option specifically because of this FDA-recognized benefit. Discuss both options with your prescribing physician.

What to Do If You Suspect Sleep Apnea

If you snore heavily, wake up feeling unrested despite adequate sleep time, experience morning headaches, or find yourself falling asleep during the day, talk to your doctor about a sleep study. Home sleep tests are now widely available and can diagnose OSA without an overnight lab visit.

If you’re already on a GLP-1 medication and using CPAP, monitor your AHI readings as you lose weight. Many men find they can reduce their CPAP pressure settings or eventually discontinue the device entirely as their weight drops — always under medical supervision.